Management of cytomegalovirus in hematopoietic stem cell transplant recipients: A review of novel pharmacologic and cellular therapies

Background: Despite diagnostic and therapeutic advances, cytomegalovirus (CMV) infection has remained a significant complication after hematopoietic stem cell transplantation (HSCT). The widespread use of pre-emptive antiviral therapy has reduced, but not eliminated, the occurrence of early CMV infection. The epidemiological shift of CMV infection, requiring repeated and prolonged treatment courses, creates an increasing need for novel …